Floatz logo

Idarubicine

Refractory Anemia

National Cancer Institute (NCI)Phase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Refractory Anemia cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BB
FILGRASTIM
National Cancer Institute (NCI)
Phase 3BB
METHOTREXATE
National Cancer Institute (NCI)
Phase 3BB

View all 28 →

Same molecule, other indications

Idarubicine is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
Acute Promyelocytic LeukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →